- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Robert Popovian, PharmD, MS, Discusses Biosimilar Progress and Education in the United States
As chief science policy officer for Global Healthy Living Foundation, Robert Popovian, PharmD, MS, has a bird’s-eye view of some of the central issues of biosimilar access in the United States.
The Global Healthy Living Foundation is a volunteer organization that works to improve the lives of individuals with chronic conditions. Given that, the group has a natural interest in seeing improvements in patience access to critical medicines, such as biosimilars, which are equivalent to reference biologics and can help bring down the costs of treatment.
In this interview, Tony Hagen, senior editor for The Center for Biosimilars®, talks with Robert Popovian, PharmD, MS, who serves as chief science policy officer at GHLF, about a recent podcast series the group did to promote wider understanding of biosimilars. Popovian provides his impressions of progress toward biosimilar availability in the United States and the value of biosimilar education for patients and providers.
Popovian is also vice president of Health Economics and Policy for ConsenSys Health and a senior health policy fellow at the Progressive Policy Institute. To access the podcasts on biosimilars produced by GHLF, use this link.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA
September 14th 2024A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.
The Future of Biosimilar Gene Therapies: Key Issues and Potential
September 11th 2024While biosimilars could potentially lower costs and improve access to gene therapies, significant hurdles in regulation, manufacturing, intellectual property, and market size pose challenges to their development and market entry.
